Immune response against SARS-CoV-2 vaccinatio
- Conditions
- COVID-19
- Registration Number
- DRKS00028174
- Lead Sponsor
- DKFZ
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
healthy who can give informed consent
Exclusion Criteria
Volunteers who suffer from chronic or acute direct (infections, autoimmunity, tumors, congenital) or indirect (drug induced) immune defects
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The overall goal of the study is a detailed longitudinal characterisation of the B- and T-Zell response in peripheral blood after SARS-CoV-2 mRNA vaccination. The study aims to provide fundamental molecular, cellular and functional insights in the development and quality of B- and T-cell responses on single-cell level.
- Secondary Outcome Measures
Name Time Method same as primary outcome